Cytokinetics Inc - Company Profile
Powered by 
All the data and insights you need on Cytokinetics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cytokinetics Inc Strategy Report
- Understand Cytokinetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates which is designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
350 Oyster Point Boulevard, South San Francisco, California, 94080
Website
cytokinetics.com
Telephone
1 650 6243000
No of Employees
409
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CYTK (NASD)
Revenue (2022)
$94.6M
34.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-80.6%
(2022 vs 2021)
Market Cap*
$3.4B
Net Profit Margin (2022)
XYZ
-34.5%
(2022 vs 2021)
* As of and is in US$
Cytokinetics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Omecamtiv Mecarbil: Heart Failure |
| Reldesemtiv: Spinal Muscular Atrophy and Chronic Obstructive Pulmonary Disease |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In April, the company announced to discontinue its Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis. |
| 2022 | Contracts/Agreements | In May, the company and The ALS Association announced the continuation of their partnership in the fight against ALS. |
| 2022 | Regulatory Approval | In February, the company secured FDA approval for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction. |
Competitor Comparison
| Key Parameters | Cytokinetics Inc | Regeneron Pharmaceuticals Inc | Alexion Pharmaceuticals Inc | Mitsubishi Tanabe Pharma Corp | PTC Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
| City | South San Francisco | Tarrytown | Boston | Osaka | South Plainfield |
| State/Province | California | New York | Massachusetts | Osaka | New Jersey |
| No. of Employees | 409 | 11,851 | 3,000 | 6,697 | 1,402 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John T. Henderson, M.D. | Chairman | Executive Board | 2022 | 78 |
| Robert I. Blum | President; Director; Chief Executive Officer | Executive Board | 2007 | 59 |
| Ching W. Jaw | Senior Vice President; Chief Financial Officer | Senior Management | 2017 | 60 |
| Robert C. Wong | Vice President; Chief Accounting Officer | Senior Management | 2019 | 56 |
| Kari K. Loeser | Chief Compliance Officer; Vice President | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward